Suppr超能文献

OXA-48 型β-内酰胺酶赋予的抗菌药物耐药性:迈向深入的机制理解。

Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding.

机构信息

School of Biochemistry, University of Bristol, Bristol, United Kingdom

Centre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00184-21.

Abstract

OXA-48-type β-lactamases are now routinely encountered in bacterial infections caused by carbapenem-resistant These enzymes are of high and growing clinical significance due to the importance of carbapenems in treatment of health care-associated infections by Gram-negative bacteria, the wide and increasing dissemination of OXA-48 enzymes on plasmids, and the challenges posed by their detection. OXA-48 confers resistance to penicillin (which is efficiently hydrolyzed) and carbapenem antibiotics (which is more slowly broken down). In addition to the parent enzyme, a growing array of variants of OXA-48 is now emerging. The spectrum of activity of these variants varies, with some hydrolyzing expanded-spectrum oxyimino-cephalosporins. The growth in importance and diversity of the OXA-48 group has motivated increasing numbers of studies that aim to elucidate the relationship between structure and specificity and establish the mechanistic basis for β-lactam turnover in this enzyme family. In this review, we collate recently published structural, kinetic, and mechanistic information on the interactions between clinically relevant β-lactam antibiotics and inhibitors and OXA-48 β-lactamases. Collectively, these studies are starting to form a detailed picture of the underlying bases for the differences in β-lactam specificity between OXA-48 variants and the consequent differences in resistance phenotype. We focus specifically on aspects of carbapenemase and cephalosporinase activities of OXA-48 β-lactamases and discuss β-lactamase inhibitor development in this context. Throughout the review, we also outline key open research questions for future investigation.

摘要

OXA-48 型β-内酰胺酶现在经常在由耐碳青霉烯的革兰氏阴性菌引起的细菌感染中遇到。由于碳青霉烯类药物在治疗革兰氏阴性菌引起的医疗相关性感染中的重要性、OXA-48 酶在质粒上的广泛和不断增加的传播以及它们检测所带来的挑战,这些酶具有很高且不断增加的临床意义。OXA-48 赋予青霉素(被有效水解)和碳青霉烯类抗生素(被缓慢分解)耐药性。除了亲本酶外,现在越来越多的 OXA-48 变体正在出现。这些变体的活性谱不同,有些水解扩展谱的氧肟基头孢菌素。OXA-48 组的重要性和多样性的增长促使越来越多的研究旨在阐明结构与特异性之间的关系,并确定该酶家族中β-内酰胺转化的机制基础。在这篇综述中,我们汇集了最近发表的关于临床相关β-内酰胺抗生素和抑制剂与 OXA-48 类β-内酰胺酶之间相互作用的结构、动力学和机制信息。总的来说,这些研究开始形成一个详细的画面,说明了 OXA-48 变体之间β-内酰胺特异性差异以及由此产生的耐药表型差异的基础。我们特别关注 OXA-48 类β-内酰胺酶的碳青霉烯酶和头孢菌素酶活性的各个方面,并在这方面讨论β-内酰胺酶抑制剂的开发。在整个综述中,我们还概述了未来研究的关键开放性研究问题。

相似文献

1
Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00184-21.
2
OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0021622. doi: 10.1128/aac.00216-22. Epub 2022 Jul 20.
3
Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01172-17. Print 2017 Nov.
4
Penicillin sulfone inhibitors of class D beta-lactamases.
Antimicrob Agents Chemother. 2010 Apr;54(4):1414-24. doi: 10.1128/AAC.00743-09. Epub 2010 Jan 19.
6
Mechanistic Basis of OXA-48-like β-Lactamases' Hydrolysis of Carbapenems.
ACS Infect Dis. 2021 Feb 12;7(2):445-460. doi: 10.1021/acsinfecdis.0c00798. Epub 2021 Jan 25.
8
An Extended Reservoir of Class-D Beta-Lactamases in Non-Clinical Bacterial Strains.
Microbiol Spectr. 2022 Apr 27;10(2):e0031522. doi: 10.1128/spectrum.00315-22. Epub 2022 Mar 21.
9
[MULTIRESISTANT BACTERIA].
Acta Med Croatica. 2015 Sep;69(3):211-6.
10
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.
Int J Mol Sci. 2020 Dec 6;21(23):9308. doi: 10.3390/ijms21239308.

引用本文的文献

4
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
5
Rapidly spreading with OXA-48-like carbapenemases.
J Clin Microbiol. 2025 Feb 19;63(2):e0151524. doi: 10.1128/jcm.01515-24. Epub 2025 Jan 6.
6
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.
Antibiotics (Basel). 2024 Jul 5;13(7):629. doi: 10.3390/antibiotics13070629.
7
Drug Discovery in the Field of β-Lactams: An Academic Perspective.
Antibiotics (Basel). 2024 Jan 8;13(1):59. doi: 10.3390/antibiotics13010059.
8
An Ion-Pair Induced Intermediate Complex Captured in Class D Carbapenemase Reveals Chloride Ion as a Janus Effector Modulating Activity.
ACS Cent Sci. 2023 Dec 13;9(12):2339-2349. doi: 10.1021/acscentsci.3c00609. eCollection 2023 Dec 27.
10
Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Collected as Part of a Global Surveillance Study, 2018 to 2019.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0140622. doi: 10.1128/aac.01406-22. Epub 2023 Apr 19.

本文引用的文献

1
Mechanistic Basis of OXA-48-like β-Lactamases' Hydrolysis of Carbapenems.
ACS Infect Dis. 2021 Feb 12;7(2):445-460. doi: 10.1021/acsinfecdis.0c00798. Epub 2021 Jan 25.
2
Analysis of β-lactone formation by clinically observed carbapenemases informs on a novel antibiotic resistance mechanism.
J Biol Chem. 2020 Dec 4;295(49):16604-16613. doi: 10.1074/jbc.RA120.014607. Epub 2020 Sep 22.
3
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
J Med Chem. 2020 Nov 12;63(21):12511-12525. doi: 10.1021/acs.jmedchem.0c00579. Epub 2020 Jul 24.
6
Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries.
ACS Infect Dis. 2020 May 8;6(5):1214-1227. doi: 10.1021/acsinfecdis.0c00015. Epub 2020 Mar 25.
7
Substrate Specificity of OXA-48 after β5-β6 Loop Replacement.
ACS Infect Dis. 2020 May 8;6(5):1032-1043. doi: 10.1021/acsinfecdis.9b00452. Epub 2020 Mar 19.
9
Epidemiology of β-Lactamase-Producing Pathogens.
Clin Microbiol Rev. 2020 Feb 26;33(2). doi: 10.1128/CMR.00047-19. Print 2020 Mar 18.
10
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Int J Antimicrob Agents. 2020 Jul;56(1):105925. doi: 10.1016/j.ijantimicag.2020.105925. Epub 2020 Feb 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验